Free Trial

Andean Precious Metals Q2 2024 Earnings Report

Andean Precious Metals logo
C$1.29 +0.09 (+7.50%)
As of 01/8/2025

Andean Precious Metals EPS Results

Actual EPS
C$0.08
Consensus EPS
C$0.08
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Andean Precious Metals Revenue Results

Actual Revenue
$95.47 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Andean Precious Metals Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Andean Precious Metals Earnings Headlines

Andean Precious Metals Corp. (APM.TO)
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
See More Andean Precious Metals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Andean Precious Metals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Andean Precious Metals and other key companies, straight to your email.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

View Andean Precious Metals Profile

More Earnings Resources from MarketBeat